|Articles|August 1, 2002
- Applied Clinical Trials-08-01-2002
Developing New Drugs in 1000 Days
Everybody wants faster cycles and and quicker turnarounds with NDAs. In the U.S., will it soon be possible to go from testing to approval in 1000 days?
Advertisement
Articles in this issue
about 23 years ago
Cross-(Dys)Functional Teamsabout 23 years ago
Checking In on Children, Checking Up on Filesabout 23 years ago
eSource Reduxabout 23 years ago
New User Fee Program Aims to Spur Drug Developmentabout 23 years ago
Paper vs. Electronic DiariesNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
The Value of Pragmatic Randomized Clinical Trials: Strategic Approaches for Real-World Impact
4
Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
